You are here

Kulchaya Sheaya Lender capsules

Safety advisory

5 December 2019

Kulchaya Sheaya Lender capsules pose a serious risk to your health and should not be taken.

The Therapeutic Goods Administration (TGA) has tested a product labelled Kulchaya Sheaya Lender capsules and found that:

  • The Kulchaya Sheaya Lender capsules contain the undeclared substance Fluoxetine.

Fluoxetine is the active ingredient used and marketed for the treatment of depression.

Consumers are advised that Fluoxetine is a prescription-only (S4) medicine in Australia.

The supply of Kulchaya Sheaya Lender capsules containing the undisclosed Fluoxetine is illegal.

Kulchaya Sheaya Lender capsules have not been assessed by the TGA for quality, safety or efficacy as required under Australian legislation, and the place of manufacture is not approved by the TGA.

Information for consumers

  • Stop taking Kulchaya Sheaya Lender capsules and take any remaining capsules to your local pharmacy for safe disposal.
  • If you have any concerns arising from your use of this product, consult your health care practitioner.

Action the TGA is taking

The TGA is working with the Australian Border Force (ABF) to help stop future shipments of Kulchaya Sheaya Lender capsules from entering Australia.

If these capsules are found at the border by the ABF they will be seized and destroyed.

The TGA is advising consumers to exercise extreme caution when purchasing medicines from unknown overseas Internet sites and has produced a short video on the risks associated with buying medicines and medical devices online. Products purchased over the Internet:

  • may contain undisclosed and potentially harmful ingredients
  • may not meet the same standards of quality, safety and efficacy as those approved by the TGA for supply in Australia.

Report counterfeit medicines and medical devices

If you are worried about counterfeit medicines or medical devices, and want to report an issue, you can report the matter to the TGA:

Phone: 1800 020 653

Online: Report a perceived breach of the Therapeutic Goods Act or questionable practices relating to therapeutic products

Email: